Navigation Links
Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Date:9/25/2007

nsomnia and agitation may be associated with depression. In addition to its anti-depressive effects, trazodone has some sedative effects that can improve sleep. Labopharm's once-daily formulation has been specifically designed to take advantage of trazodone's unique pharmacological properties, in addition to offering the benefits of once-daily administration and potentially fewer side effects generally associated with peak concentrations of drugs.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the outcomes of clinical trials, the regulatory process for drug approval and the commercialization of the Company's products, if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. iGATE Completes Phase I Testing Of Meningitis Vaccine
2. Delhi Hospital Completes 100 Liver Transplants
3. Roche Completes Acquisition of BioVeris
4. FDA approves Phase 0 trial which tests experimental drugs on humans
5. SARS-Free Taiwan to Mark End Phase of Global Fight
6. S. Africa AIDS in death phase
7. Spray on contraceptive clears Phase I trial
8. Phase 3 trials of two multi-kinase inhibitors against cancer
9. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
10. Phase II trails of new HIV vaccine to be held in South Africa
11. Phase 1 Drug Trials on Humans to Be Made Public
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)NEW ORLEANS, Dec. 5 Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology int
(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation
(Date:12/4/2009)SAN FRANCISCO, Dec. 4 Medithrive, Inc. has won the Patient,s Choice Award as the favorite dispensary in the SF Bay Area by popular vote conducted by the online website, www.weedmaps.com. Despite on
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
Breaking Medicine News(10 mins):Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
...reports 21% sequential growth in domestic handpiec...is,Corporation (Pink Sheets: CGCP), a leading deve... angina-relieving procedures, today reported,finan...first quarter sales of $3,370,000. During the firs...
...Simmons Kicks-Off National Sampling Initiative wit... NYC,s Penn Station, LAKEVILLE-MIDDLEBORO, Mass.,...to energize the country and lift people from,Ameri...eople need an extra boost to keep them on the go. ...
..., May 15 MS -- "Eat your vegetables!" is a plea,o...that many young children,don,t seem to like vegeta...,fact, developed prenatally," says Jane Kostelc, e...s that unborn babies may detect,taste differences ...
...g to a new study from the University of Minnesota,...ced skin cancer may have been identified. The rese...cer in response to sun exposure is in receptor mol...earch appears in the May 15 issue of Cancer Resear...
... FL, May 19, 2008 Losing weight may help resolve ...search presented today at the 103rd Annual Scienti... (AUA). Morbid obesity can cause sexual dysfunctio... sexual function was normalized in some men who un...
... FL, May 21, 2008Men with greater access to prosta...comes from the disease, a new study shows. Urologi...eased numbers of screening programs and decreased ... Surveillance System of the Centers for Disease Co...
Other Medicine News:Health News:Cardiogenesis Reports First Quarter 2008 Results 2Health News:Cardiogenesis Reports First Quarter 2008 Results 3Health News:Cardiogenesis Reports First Quarter 2008 Results 4Health News:Cardiogenesis Reports First Quarter 2008 Results 5Health News:Cardiogenesis Reports First Quarter 2008 Results 6Health News:Video: Ocean Spray Revitalizes Americans Naturally With Free Fuel for Their Bodies 2Health News:Eat Your Vegetables - That Means You, Parents! 2Health News:U of Minnesota researcher discovers the starting point of sun-induced skin cancer 2
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
(Date:12/3/2009)DOYLESTOWN, Pa., Dec. 3 Ted Karkus, Chairman and CEO of The Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com announced today that the Company has completed its evaluation of its opportunitie
(Date:12/3/2009)WILMINGTON, Del., Dec. 3 ParagonRx, a Delaware-based company specializing in pharmaceutical risk management and optimal medication use, will host a free webinar on Wednesday, Dec. 9, on the FDA,s dra
Breaking Medicine Technology:Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3Company Reverses Course 3A The Billboard Roy Blunt Doesnt Want You To See Will Go Up After All 54571 1Company Reverses Course 3A The Billboard Roy Blunt Doesnt Want You To See Will Go Up After All 54571 2AMDL Inc Files Notification of Late Filing for Form 10 Q 54569 1AMDL Inc Files Notification of Late Filing for Form 10 Q 54569 2Statewide program to improve emergency care for children 54567 1Statewide program to improve emergency care for children 54567 2
At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed)
Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial
Other Medicine Technology:At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 2At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 3At the 2007 Alzheimer's Association International Conference on the,Prevention of Dementia - Neurochem's U.S. Principal Investigator,Presents Update on Tramiprosate (Alzhemed) 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 2Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 3Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 4Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 5Valopicitabine Combined with Standard of Care Cleared Hepatitis C,Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a,Phase II Trial 6
BEP/1Q-PAL-ERB - Polished Aluminum Base - Model 1Q51-R-PAL-ERB
BEN/1Q-CAB-ERB - Reinforced Nylon Base - Model 1Q66-R-CAB-ERB
...large backrests with lumbar support • Select ...rs and glides. • Choose the BE Series for top...g: industry, education, laboratory, clean room, st...reinforced nylon base • unit standard with ca...
...large backrests with lumbar support • Select ...rs and glides. • Choose the BE Series for top...g: industry, education, laboratory, clean room, st...reinforced nylon base • unit standard with ca...
Medicine Products: